SecBot SecBot
8-K ·Filed Nov 10, 2026

PALI

PALISADE BIO, INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed6d 10h ago SEC0001357459-26-000025
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the ASCENTRA-UC topline readout in Q4 2027, with ASCENTRA-CD enrollment initiation in Q1 2027 as a near-term milestone. Cash runway through both readouts reduces near-term financing risk, but the widening net loss and cash burn rate warrant monitoring of the burn trajectory.

DirectionNeutral
Confidencehigh
Horizonmonths

PALI-2108

● Neutral Named in this 8-K
Impact
Phase
Phase 2b
Time to market
If Phase 2b succeeds, PALI-2108 would need to advance to Phase 3 trials and then file for FDA approval, a process that typically takes several more years. The earliest potential approval would likely be 2029-2030 at the earliest, assuming successful trials.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 2b ASCENTRA-UC topline data expected in Q4 2027, roughly 12 months away. Positive data would validate PALI-2108's differentiated gut-targeted PDE4 approach in a large, well-controlled study; negative or mixed results would severely impact the stock since PALI-2108 is the company's only clinical-stage asset. Interim milestones to watch include ASCENTRA-CD (Crohn's) first patient dosing targeted for Q1 2027 and any early data presentations at medical conferences.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.17
T+0 close · Nov 10, 2026 · via day close
Latest settled
−2.56%
T+1 · $1.14
Vs SPY
−2.21%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $1.17entry
  2. T+1 · 5d ago −2.56%α −2.21% · $1.14
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palisade Bio reported Q3 2026 net loss of $14.6M ($0.07 per share), wider than the $2.9M loss a year ago, as R&D spending surged to $10.6M to support Phase 2 trials. The key operational milestone was dosing the first patient in the Phase 2b ASCENTRA-UC trial on October 27, 2026, with topline results expected in Q4 2027. Cash of $113.6M is expected to fund operations through both ASCENTRA-UC and ASCENTRA-CD readouts.

Key Financial Metrics

EPS
−$0.07
Revenue
$0.00
est $0.00

Key Facts

  • First patient dosed in Phase 2b ASCENTRA-UC trial on October 27, 2026; topline results expected Q4 2027
  • FDA cleared IND for Phase 2a ASCENTRA-CD trial on September 22, 2026; enrollment targeted for Q1 2027
  • Net loss of $14.6M for Q3 2026 vs $2.9M in Q3 2025; net loss per share $0.07 vs $0.38
  • R&D expenses $10.6M in Q3 2026 vs $1.4M in Q3 2025, driven by Phase 2 start-up costs
  • Cash and cash equivalents $113.6M as of September 30, 2026, down from $125.2M at June 30, 2026
  • Cash runway expected to fund operations through primary efficacy readouts from both Phase 2 trials

Financial Impact

Q3 2026 net loss $14.6M, cash burn $19.8M year-to-date; cash position $113.6M

net losscash and cash equivalentsR&D expenses

Risk Factors

  • Clinical trial enrollment delays or failure to meet endpoints in Phase 2 studies
  • Cash burn rate of ~$20M per nine months may require additional financing before readouts
  • No approved products or revenue; pre-revenue clinical-stage company

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001357459-26-000025
Document: pali-20261110.htm0001357459-26-000025
Document: 0001357459-26-000025-index-headers.html0001357459-26-000025
Document: 0001357459-26-000025-index.html0001357459-26-000025
Document: 0001357459-26-000025.txt0001357459-26-000025
8-K Data (Synthetic)0001357459-26-000025

Track record

14 reports on PALI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $1.17 Now $1.03 −11.97% settles Dec 10
  3. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
  4. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
  5. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
  6. Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
  7. Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
  8. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
  9. Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
  10. Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026